Allergy Point-Of-Care Testing Market Size In 2026: Growth Outlook And Forecast Through 2030
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Allergy Point-Of-Care Testing Market Growth From $1.49 Billion In 2026 To $2.34 Billion By 2030 At A CAGR Of 12%
The allergy point-of-care testing market size has experienced rapid expansion in recent years. It is projected to increase from $1.33 billion in 2025 to $1.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.8%. The growth observed in preceding periods can be attributed to a global rise in the prevalence of allergic disorders, growing clinical recognition of early allergy diagnosis, the advancement of immunoassay technologies in diagnostics, an expanding infrastructure for hospital-based laboratory testing, and an escalation in pediatric allergy cases.
The allergy point-of-care testing market is anticipated to experience significant expansion over the coming years. Its valuation is projected to reach $2.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. This projected increase during the forecast period stems from factors such as the wider uptake of point-of-care diagnostic methods, advancements in personalized medicine for allergy treatment, a growing need for quick home-based testing options, the incorporation of AI-powered diagnostic interpretation tools, and the ongoing trend of healthcare decentralization along with the expansion of outpatient services. Key trends anticipated in the same period encompass the growing acceptance of rapid immunoglobulin E-based allergy diagnostics, a heightened demand for portable point-of-care testing equipment, the broadening of decentralized allergy screening within primary care environments, the proliferation of immunoassay-based rapid allergy detection kits, and the greater integration of digital health platforms into allergy testing processes.
Get A Free Sample Report With In-Depth Market Insights:
Allergy Point-Of-Care Testing Market Growth Drivers: What’s Behind The Acceleration?
The expanding occurrence of allergic conditions is projected to boost the allergy point of care testing market in the coming years. These conditions represent immune system dysfunctions where the body reacts excessively to innocuous substances, manifesting in symptoms like sneezing, skin irritations, and breathing difficulties. The escalation in allergic conditions is linked to greater exposure to environmental allergens, including pollen, dust, and pollution, which provoke immune system overreactions in prone individuals. Allergy point-of-care testing facilitates quick and accessible identification of specific allergens, empowering healthcare providers to promptly determine triggers, formulate tailored treatment strategies, and assist people in managing and mitigating the effects of allergic conditions efficiently. For instance, in November 2025, Asthma Australia, an Australia-based non-profit organization, reported that 322 women died from asthma last year compared with 156 men, a figure more than double. This trend has persisted since 2023, with half of the 478 total deaths affecting women aged 75 and over. Consequently, the growing incidence of allergic conditions is propelling the expansion of the allergy point of care testing market. The increasing outlay on healthcare is anticipated to stimulate the expansion of the allergy point-of-care testing market in the future. Healthcare expenditure encompasses the total financial resources allocated by governments, private entities, and individuals towards health services, medical goods, public health programs, and healthcare infrastructure. This expenditure is expanding owing to a heightened demand for medical services, as a greater number of patients seek consultations, treatments, and diagnostic evaluations, thereby increasing overall healthcare spending. Elevated healthcare spending fosters the growth of allergy point-of-care (POC) testing by facilitating investment in cutting-edge diagnostic tools, enabling swift testing at or close to patient care locations, lessening dependence on central laboratories, and enhancing overall healthcare efficiency and results. For instance, in January 2026, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that in 2024, National Health Expenditure (NHE) rose by 7. 2% to attain $5. 3 trillion, averaging $15,474 per person, and constituted 18. 0% of the Gross Domestic Product (GDP). As a result, the upward trend in healthcare expenditure is fueling the growth of the allergy point-of-care testing market.
Allergy Point-Of-Care Testing Market Segment Analysis: What Are The Core Market Categories?
The allergy point-of-care testing market covered in this report is segmented –
1) By Product Type: Rapid Specific Immunoglobulin E Kits, Skin Prick Testing Kits, Rapid Anaphylaxis Kits, Sample Collection Devices, Analyzers
2) By Sample Type: Blood, Serum Or Plasma, Fingerstick Whole Blood
3) By Allergen Type: Food Allergens, Environmental Allergens, Drug And Insect Venom Allergens
4) By Application Focus: Primary Care Triage, Pediatric Clinic Workups, Emergency Care Support, Occupational Health Screening, Pharmacy Led Testing
5) By End User: Specialty Clinics, Hospitals, Retail Pharmacies, Occupational Health Providers, Direct To Consumer
Subsegments:
1) By Rapid Specific Immunoglobulin E Kits: Food Allergy Kits, Inhalant Allergy Kits, Drug Allergy Kits, Environmental Allergy Kits
2) By Skin Prick Testing Kits: Standard Allergen Panels, Custom Allergen Panels, Pediatric Testing Kits, Adult Testing Kits
3) By Rapid Anaphylaxis Kits: Epinephrine Auto Injectors, Immediate Reaction Detection Kits, Allergic Response Monitoring Kits, Emergency Response Kits
4) By Sample Collection Devices: Blood Collection Devices, Saliva Collection Devices, Skin Prick Sampling Devices, Capillary Sampling Devices
5) By Analyzers: Immunoassay Analyzers, Chemiluminescence Analyzers, Integrated Analyzer Systems, Portable Point Of Care Analyzers
Allergy Point-Of-Care Testing Market Trends: What’s Defining The Industry’s Next Phase?
Companies operating in the allergy point-of-care testing market are prioritizing the creation of innovative products, such as semi-quantitative point-of-care diagnostic devices, to deliver swift and accurate allergy test results within clinical environments. These semi-quantitative point-of-care diagnostic devices are tools designed to measure approximate concentrations of specific biomarkers, including IgE, directly at the clinic, yielding rapid, dependable results that empower healthcare providers to quickly assess the severity of allergic responses and make immediate, informed treatment decisions without the delay of traditional laboratory tests. As an illustration, in June 2024, Kenota Health, a Canada-based medical technology company, obtained U. S. Food and Drug Administration (FDA) clearance and a CLIA waiver for its Kenota 1 Total IgE test system, allowing its deployment in point-of-care clinical settings. The Kenota 1 system functions as a semi-quantitative diagnostic device that measures total IgE levels from a minimal fingerstick blood sample, providing results in under 30 minutes through automated operation, which contrasts with traditional laboratory IgE tests that necessitate venous blood draws and several days for results. The system is engineered for rapid, in-office allergy assessment, offering features such as a small blood volume requirement of 4. 5 microliters per test, user-friendly operation, and the capacity to run 15–60 tests per session. Its applications include supporting the diagnosis of IgE-mediated allergic disorders and enabling clinicians to make immediate patient care decisions, thereby streamlining allergy management and improving patient outcomes.
Allergy Point-Of-Care Testing Market Industry Leaders And Competitive Landscape
Major companies operating in the allergy point-of-care testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Hitachi Chemical Diagnostic Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Eurofins Scientific SE, bioMérieux SA, Quidel Corporation, EUROIMMUN Medizinische Labordiagnostika AG, R-Biopharm AG, HOB Biotech Group Corp. Ltd., Hycor Biomedical Inc., Omega Diagnostics Ltd, Lincoln Diagnostics Inc., Alerchek Inc., Abionic SA, Kenota Health Inc.
View The Full Allergy Point-Of-Care Testing Market Report:
Allergy Point-Of-Care Testing Market Regional Analysis And Leading Geography
North America was the largest region in the allergy point-of-care testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allergy point-of-care testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
